N/A N=43 Randomized Single-blind Treatment

Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes

Type 1 Diabetes

Bottom Line

View on ClinicalTrials.gov: NCT02777073 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2024

Primary outcome: Primary: Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin — 0.08; 0.25; 0.21 mM

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Victoza (Drug); Placebo (Drug); Dapagliflozin 10mg Tab (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University at Buffalo
Primary completion: Dec 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin	0.08; 0.25; 0.21	—
SECONDARY Change in Glucagon Levels.	-19; 1; -15	—
SECONDARY Change in Free Fatty Acid (FFA) Concentrations	0.1; 0.17; 0.11	—
SECONDARY Change in Ghrelin Concentrations	-32; 66; 32	—

Summary

1. To compare levels of ketone bodies (beta-hydroxybutyrate and acetoacetate) in plasma and urine following a single dose treatment of either liraglutide 1.8mg, dapagliflozin 10mg or placebo in insulinopenic state. 2. To compare plasma levels of free fatty acid, glucagon, hs-CRP, Ll-6 and IL-1 before and after administration of liraglutide/placebo.

Eligibility Criteria

Inclusion Criteria

Type 1 Diabetes on continuous subcutaneous insulin infusion (CSII, also known as insulin pump).
Undetectable c peptide (c-peptide 3 times normal) or Cirrhosis
Renal impairment (serum eGFR 500 mg/dl).
Those with history of bladder cancer , diabetic ketoacidosis

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02777073). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.